



**THE FIRST AND ONLY NON-HORMONAL
NEUROKININ B (NKB) ANTAGONIST**
INDICATED IN THE TREATMENT OF VMS
ASSOCIATED WITH MENOPAUSE.^{1-3*}


**NON-HORMONAL*
NKB ANTAGONIST**

DISCOVER VEOZAH

FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS (VMS), COMMONLY REFERRED TO AS HOT FLASHES AND NIGHT SWEATS.⁴


VEOZAH (fezolinetant film-coated tablets) is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

PATHOPHYSIOLOGY OF VMS



Explore the mechanism of action of VEOZAH

HOW VEOZAH WORKS[†]



KNDy: kisspeptin/neurokinin B/dynorphin; NK3: neurokinin 3; NKB: neurokinin B; VMS: vasomotor symptoms.

*Comparative clinical significance is unknown.

[†] Clinical significance is unknown.

Scan the QR code on the next page to watch the mechanism of action video of VEOZAH.

Pr **VEOZAH**[®]
fezolinetant 45mg
tablets

**THE FIRST AND ONLY NON-HORMONAL
NEUROKININ B (NKB) ANTAGONIST**
INDICATED IN THE TREATMENT OF VMS
ASSOCIATED WITH MENOPAUSE.^{1-3*}

**NON-HORMONAL*
NKB ANTAGONIST**

VEOZAH is a selective neurokinin 3 (NK3) receptor antagonist.[†]

Blocks
**THE BINDING
OF NKB**

On the
KNDy NEURON

Modulating
**NEURONAL
ACTIVITY IN THE
THERMOREGULATORY
CENTER IN THE
HYPOTHALAMUS***



Scan the code to explore the mechanism
of action of VEOZAH

Consult the Product Monograph at www.veozahmonograph.ca for important information relating to:

- Contraindications in patients with known cirrhosis, severe renal impairment or end-stage renal disease, using concomitant moderate or strong CYP1A2 inhibitors, with known or suspected pregnancy, hypersensitive to the drug or to any ingredient in the formulation.
- Relevant warnings and precautions regarding incidence of other malignancies, known or previous breast cancer or estrogen-dependent malignancies, endometrial hyperplasia and endometrial carcinoma, patients with moderate or severe hepatic impairment (Child Pugh Class B or C), hepatic transaminase elevation and hepatotoxicity, hepatic function and injury monitoring, and breast-feeding.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling **1-888-338-1824**.

KNDy: kisspeptin/neurokinin B/dynorphin, NK3: neurokinin 3, NKB: neurokinin B, VMS: vasomotor symptoms.

*Comparative clinical significance is unknown.

† Clinical significance is unknown.

REFERENCES: 1. VEOZAH Product Monograph. Markham, ON: Astellas Pharma Canada, Inc. 2. The North American Menopause Society (NAMS). *Menopause*. 2023;30(6):573-590. 3. Data on file. Astellas Pharma Canada, Inc. 4. Yuksel N, Evaniuk D, Huang L, et al. Guideline No. 422a: Menopause: vasomotor symptoms, prescription therapeutic agents, complementary and alternative medicine, nutrition, and lifestyle. *J Obstet Gynaecol Can*. 2021 Oct;43(10):1188-1204.e1.



All trademarks are the property of their respective owners.
© 2025 Astellas Pharma Inc. or its affiliates.
MAT-CA-VEO-2024-00012 03/25


VEOZAH[®]
fezolinetant 45mg
tablets